We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Regulatory T cells function at the early stage of tumor progression in a mouse model of tongue squamous cell carcinoma.
- Authors
Miki, Kentaro; Orita, Yorihisa; Gion, Yuka; Takao, Soshi; Ohno, Kyotaro; Takeuchi, Mai; Ito, Toshihiro; Hanakawa, Hiroyuki; Tachibana, Tomoyasu; Marunaka, Hidenori; Makino, Takuma; Minoura, Akira; Matsukawa, Akihiro; Nishizaki, Kazunori; Yoshino, Tadashi; Sato, Yasuharu
- Abstract
The objective of this study was to observe the distribution of regulatory T cells (Tregs) in the development of tongue squamous cell carcinoma (SCC) and to determine the role of Tregs in the progression of tongue SCC. A mouse model of 4-nitroquinoline-1-oxide (4NQO)-induced-tongue SCC was established. The expression of Forkhead box P3 (Foxp3), interleukin 10, transforming growth factor-β, chemokine CC motif ligands 17, 20, and CC chemokine receptor 4 was determined using real-time quantitative polymerase chain reaction. Foxp3 expression was also analyzed using immunohistochemistry. The results were compared with those of control mice and of 4NQO-treated mice treated with a cyclooxygenase-2 (COX-2) inhibitor. Well to moderately differentiated tongue SCC was induced in all of the experimental mice. The amount of Tregs of the experimental mice was over 10 times as much as control mice at the early stage of tumor progression. COX-2 inhibitor did not prevent the progression of tongue SCC and did not reduce the total amount of Tregs. Tregs function at the early stage of the development of tongue SCC, and it may be effective to suppress Tregs at the early stage of tumor progression for the treatment and/or prevention of tongue SCC.
- Subjects
IMMUNOHISTOCHEMISTRY; CANCER invasiveness; CYCLOOXYGENASE 2; SQUAMOUS cell carcinoma; TONGUE cancer; LABORATORY mice; PREVENTION; CANCER treatment
- Publication
Cancer Immunology, Immunotherapy, 2016, Vol 65, Issue 11, p1401
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-016-1902-x